valu usd unless otherwis note
near term strength enough off-set investor
concern sector
view report strong quarter beat ep estim
call manag note continu face challeng gener
price environ slow-down brand inflat compani
despit better expect result reiter guidanc
revenu growth rate account drug price trend
report strong result report ep
y/i beat street estim revenu
modestli beat street estim ex-
pharmedium troubl memphi manag said begun
product begin ship commerci august good
quarter compani reiter ep guidanc rang
though said continu expect ep come
lower end rang expect oper profit
segment declin previous adjust tax rate
previous
question revolv around drug price pharmedium manag
note buy-sid gener deflat continu trend rang
quarter expect similar rate go forward iqvia data
show moder gener deflat june could provid
modest posit surpris brand inflat manag cite
numer delay mid-year brand price increas potenti
soften result revenu brand
side tie inflat fear meaning sustain downturn
inflat could weigh estim well reopen
pharmedium modest posit though expect facil slowli
ramp shipment make contribut result like modest
adjust estim lower ep estim
put estim in-lin manag expect
lower end impli ep guid quarter
decreas driven reduct y/i distribut organ revenu
growth rate expect growth segment vs prior
estim driven slower brand inflat steadi gener
deflat well slight decreas oper margin higher
sg expens ep estim essenti unchang
maintain sector perform maintain sector perform rate
lower price target share price target
equal ep estim lower price-to-earnings
multipl two turn roll estim forward reflect
unusu level industri uncertainti relat pend regulatori
effort drug price
price prior trade day market close estimate unless otherwis note
believ share like multipl rang bound
investor get visibl gener drug price
bottom oper earn growth resum
pressur last
month multipl issu relat drug price
weigh result expect backdrop
improv next month howev believ
best-posit wholesal
meet earn target given conserv guidanc
relationship walgreen though note
rel strength seem reflect current share
estim gener profit
core us drug distribut busi sale gener
drug past two year seen
price gener drug deflat high-single-digit mid-
teen percentag rate profit dollar contribut
fall slightli lower rate gener deflat continu
high-single-digit pace higher believ
volum growth abl
grow earn segment though may best
posit creat spread price fall
upsid risk sector perform rate share
includ stabil drug price environ
could caus earn estim stabil like drive
multipl expans close market multipl
downsid risk sector perform rate includ
acceler drug price deterior gener
market potenti client loss wholesal
sell-sid price compress larger pharmaci
custom gpo
bloomberg capit market estim upside/downside/target
price target share equal
ep estim use multipl reflect
slight discount averag forward trade
multipl share due uncertainti surround
upsid scenario share base
ep estim higher base case price-to-earnings
multipl appli ep scenario upsid scenario
ep better ep growth could
driven success partnership walgreen increas
volum across brand gener drug success capit
deploy level gener price deflat
forward multipl repres high end
normal trade rang drug wholes space
multipl like get neg
downsid scenario share base
ep estim base case price-to-earnings multipl
appli ep scenario downsid scenario
ep lower-than-expect ep could
driven worse-than-expect price environ
lower-than-expect brand gener volum lack
avail opportun forward multipl
like get posit share
result varianc tabl act commentspharmaceut on-board former adj margin perform coreoth adj adj adj gross larg custom continu performdistribut acquisfacil consol severance- intagibles- oper adj adj adj oper adj adj total adj op loss- expens tax brought fy tax guid per solid beat driven core pharma segmentavg number share marginoper marginamerisourcebergenbp changebp chang healthcar technolog distribut
exhibit put take
amerisourc put takeslowhighnotesabc ep put takescor busi brand price limit growthhd smith year benefitpharmedium memphi plant late restartlap dist center segment growthful year acquir rampshar share count reductiontot rel growthyoy healthcar technolog distribut
price target share support sector perform rate equal
ep estim use multipl reflect slight discount
averag forward trade multipl share due uncertainti surround
risk rate price target
forese upsid downsid risk sector perform rate share
upsid risk includ stabil drug price environ could caus earn
estim stabil like drive multipl expans close market multipl
downsid risk includ acceler drug price deterior gener market
potenti client loss wholesal sell-sid price compress
larger pharmaci custom gpo
pharmaceut distribut consult compani oper
distribut segment
distribut segment includ amerisourcebergen drug corpor abdc
compani amerisourcebergen consult servic abc world courier mwi
veterinari suppli busi partnership walgreen boot
allianc global drug sourc distribut product locat
good sold
segment revenu
segment revenu
amort intang
revenu
segment revenu
segment revenu
incom discontinu oper net tax
net loss attribut non-controlling interest
net incom attribut
earn per share continu oper
weight average number share
